

Brilinta[®] (ticagrelor) – First-time generic

- On May 1, 2025, [Teva launched](#) an [AB-rated](#) generic version of AstraZeneca's [Brilinta \(ticagrelor\)](#) tablets.
 - Teva was granted [180-day exclusivity](#) for the 60 mg tablet.
 - In addition, Dr. Reddy's, Hisun, Alkem/Ascend, MSN/Novadoz, [AvKare](#) and [Apotex launched](#) AB-rated generic versions of Brilinta's 90 mg tablet on May 1, 2025.
- Brilinta is approved for the following indications:
 - To reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome or a history of MI
 - To reduce the risk of a first MI or stroke in patients with coronary artery disease at high risk for such events
 - To reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤ 5) or high-risk transient ischemic attack.
- Brilinta carries a boxed warning for bleeding risk.